Enveda Biosciences Stock
HealthTechLooking to sell Enveda Biosciences stock or options?
Enveda Biosciences has developed a drug analysis platform that leverages chemical diversity and evolutionary insights to accelerate the creation of superior medicines. This innovative platform integrates machine learning, metabolomics, and robotics to assess natural samples for chemical structures and their biological activities and functions. By eliminating the need to isolate individual compounds or conduct extensive experimentation, Enveda Biosciences enables healthcare clients to develop new antibiotics and hypotensives and to identify and characterize a diverse array of molecules produced by living organisms.
Bioverge Ventures, Martin Brenner, Baillie Gifford, FPV Ventures, True Ventures, JAZZ Venture Partners, Level Ventures, Cresset Partners, Premji Invest (US), Amino Collective, Vertical Partners, Lifeforce Capital, Ben Cravatt, Village Global, Kevin Moore, Recursion Pharmaceuticals, Possible Ventures, Yury Popov, Ryan Shenvi, Microsoft, Kevin Lynch, Pieter Dorrestein, Dimension Capital Management, Christopher Gibson, The Nature Conservancy.